The Dubai-based Abraaj Group, a leading investor in emerging markets, and a partner, Proparco, have sold their 83 percent stake in Tunisia’s second-largest pharmaceuticals company Unimed ahead of a planned stock market listing next year, the private equity firm announced Tuesday.
Abraaj and French development agency Proparco have sold part of their holdings to a consortium of investors including Washington-based SQM, Blakeney Asset Management and the Tunisian-Kuwaiti Consortium of Development.
Neither the price nor the size of the retained stake were disclosed by Abraaj, but the firm’s statement said the partial exit is a step towards the listing of Unimed on the Tunis stock exchange in the first half of 2016.